Cancer research often involves complex and long-term treatments where patients might switch treatments, drop out, or not adhere strictly to protocols due to severe side effects or personal reasons. The ITT approach helps maintain the benefits of randomization by preserving the baseline comparability between treatment groups. This reduces bias and provides a more realistic estimate of a treatment's effectiveness in real-world clinical practice.
